Treat with foresight
nAMD

DOSING

Treat with foresight-with proactive

extended dosing with EYLEA1

nAMD

nAMD

nAMD Dosing

References:

  • EYLEA®(aflibercept solution for injection) Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG.
  • Maximum treatment interval:16weeks Minimum treatment interval:8weeks

This website contains information on EYLEA® (aflibercept solution for injection) which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission. It is intended to provide information to an international audience outside the USA and UK. In countries outside the EU the local Product Information applies.

PP-EYL-ALL-0513-1. Last updated on 29/02/2020